Melanotan I Half-Life

What Is Melanotan I's Circulating Half-Life?

Melanotan I has a circulating half-life of approximately 2 hours when administered via subcutaneous injection. This brief window means the peptide is rapidly cleared from the bloodstream, but the melanocyte stimulation it triggers persists for hours afterward. The short half-life contrasts with the extended release profile of subcutaneous implants, which provide continuous drug delivery over 60 days through a depot effect. Understanding this pharmacokinetic distinction is essential for optimizing dosing schedules and predicting response patterns.

How Does Implant Depot Release Work?

Melanotan I implants (Scenesse) consist of a compressed rod that dissolves slowly under the skin, releasing peptide continuously over 60 days. This depot mechanism provides steady-state plasma concentrations without the peaks and troughs of daily injections, resulting in more consistent melanin production. Clinical trials show that a single 16 mg implant achieves therapeutic photoprotection over the 60-day window, eliminating the burden of frequent dosing that characterizes injection-based protocols. The implant formulation was specifically engineered to overcome compliance issues associated with daily or frequent-injection regimens.

Injection Frequency and Half-Life Implications

The 2-hour half-life means injected Melanotan I requires dosing at least 3-4 times weekly for maintained effect. Some research protocols use every-48-hour dosing, balancing convenience against tanning intensity. Daily injections produce faster, more dramatic results than less frequent protocols but require greater patient compliance. The relationship between half-life and dosing frequency follows first-order kinetics: to maintain steady melanin production, users must inject before peptide concentrations drop below therapeutic thresholds. This understanding allows practitioners to customize protocols based on individual preferences and tanning goals.

Melanotan I vs Melanotan II Half-Life Comparison

Melanotan II has a slightly longer circulating half-life (approximately 4-5 hours), explaining faster tanning kinetics and why daily dosing produces more rapid visible results. This pharmacokinetic difference accounts for Melanotan II's faster onset (3-5 days visible tanning vs 7-14 days for Melanotan I) and potentially greater cumulative side effects from sustained receptor activation. The extended half-life of Melanotan II makes it more suitable for users prioritizing rapid tanning over gradual, controlled pigmentation development. However, the trade-off involves heightened side effect burden over the same cycling period.

Plasma Concentration Dynamics and Melanocyte Stimulation

After subcutaneous Melanotan I injection, peak plasma concentrations occur approximately 1-2 hours post-injection. Concentrations then decline in a first-order kinetic pattern, with 50% clearance by 2 hours and 90% clearance by 5-6 hours. Importantly, melanocyte stimulation peaks near the plasma peak but the biological effect (melanin synthesis) persists longer than circulating peptide, explaining why once-daily dosing produces cumulative effects over weeks. This pharmacodynamic offset—where cellular effects significantly outlast circulating peptide—is critical to understanding why Melanotan I's efficacy accumulates despite the brief half-life.

Storage, Stability, and Effective Half-Life in Practice

Improper storage—room temperature exposure, multiple freeze-thaw cycles, or extended refrigeration without sterile technique—degrades Melanotan I, reducing its effective half-life and potency. Reconstituted solution stored at 2-8°C maintains integrity for 30 days; beyond that, degradation increases significantly. Users who store peptides improperly may observe shortened duration of effects (visible tanning begins later, fades sooner) due to reduced biological activity and impaired receptor binding. Proper storage at -20°C for powder and 2-8°C for reconstituted solution is essential for maintaining the expected pharmacokinetic profile and therapeutic efficacy.

Optimal Dosing Intervals Based on Pharmacokinetics

Given the 2-hour half-life, optimal research protocols space injections 48-72 hours apart (3-4x weekly) to maintain melanocyte stimulation while minimizing injection burden and injection site complications. Daily dosing creates higher peak concentrations but offers only marginal improvements in tanning speed over 3x weekly protocols, often not justifying the cumulative side effect burden. For users seeking maximum convenience, every-72-hour dosing (once weekly, doubled dose) maintains adequate plasma levels for 24-48 hours, though peak-trough cycling is more pronounced. The implant formulation, with its 60-day steady-state release, represents the ultimate convenience optimization for therapeutic (EPP) use cases.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions

What is Melanotan I's exact half-life?

Approximately 2 hours in circulation. Implant-based depot release: 60 days continuous. Half-life refers to the time for 50% plasma clearance, not the duration of biological effect.

Does a longer half-life mean faster tanning?

Not necessarily. Both Melanotan I (2-hour half-life) and II (4-5 hours) achieve tanning, but frequency of dosing, not half-life alone, determines speed. Daily injections of Melanotan I tan as fast as every-other-day Melanotan II.

Why is implant duration exactly 60 days?

Implants gradually dissolve and are absorbed. 60 days represents optimal therapeutic release; beyond that, subtherapeutic concentrations occur. Longer-duration implants are under research but not yet clinically available.

Can I double my injection dose to extend effect?

Doubling dose increases peak concentrations but doesn't proportionally extend duration—clearance is concentration-independent. Instead, increase dosing frequency for sustained effect.

Does fasting affect half-life?

No. Half-life is determined by metabolic clearance rate and is independent of nutritional state. Fasting affects melanin production efficiency but not peptide half-life itself.

Is the 2-hour half-life exact for all individuals?

No. Individual variation exists based on kidney function, body composition, and hepatic metabolism. In people with renal impairment, half-life may extend to 3-4 hours. Most users experience the average 2-hour window.